{"nct_id":"NCT06956170","title":"All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-05","start_date":"2022-02-10","start_date_type":"ACTUAL","primary_completion_date":"2024-05-27","primary_completion_date_type":"ACTUAL","completion_date":"2029-11-30","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["GSK"]}